Hybrid cardiac rehabilitation trial (HYCARET): protocol of a randomised, multicentre, non-inferiority trial in South America. Issue 10 (28th October 2019)

• Record Type: Journal Article
• Authors: Serón, Pamela; Oliveros, Maria J; Marzuca-Nassr, Gabriel N; Lanas, Fernando; Morales, Gladys; Román, Claudia; Muñoz, Sergio R; Saavedra, Nicolás; Grace, Sherry L
• Is Part Of: BMJ open. Volume 9:Issue 10(2019)
• Publication Date: 2019-10-28
• Subjects: Cardiac Rehabilitation -- Exercise -- Coronary Disease -- Telerehabilitation; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-031213
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Cardiac rehabilitation (CR) programmes are well established, and their effectiveness and cost-effectiveness are proven. In spite of this, CR remains underused, especially in lower-resource settings such as Latin America. There is an urgent need to create more accessible CR delivery models to reach all patients in need. This trial aims to evaluate if the prevention of recurrent cardiovascular events is not inferior in a hybrid CR programme compared with a standard programme. Method and analysis: A non-inferiority, pragmatic, multicentre, parallel (1:1), prospective, randomised and open with blinded endpoint assessment clinical trial will be conducted. 308 patients with coronary artery disease will be recruited consecutively. Participants will be randomised to hybrid or standard rehabilitation programme. The hybrid CR programme includes 10 supervised exercise sessions and individualised lifestyle counselling by a physiotherapist, with a transition after 4–6 weeks to unsupervised delivery via text messages and phone calls. The standard CR consists of 18–22 supervised exercise sessions, as well as group education sessions about lifestyle. Intervention in both groups is between 8 and 12 weeks. The primary outcome is a composite of cardiovascular mortality and hospitalisations due to cardiovascular causes. Secondary outcomes are health-related quality of life, exercise capacity, muscle strength, heart-healthy behaviour, return-to-work, cardiovascular risk factor, adherence, and exercise-related adverse events. The outcomes will be measured at the end of intervention, at 6 months and at 12 months follow-up from recruitment. The primary outcome will be tracked through the end of the trial. Per-protocol and intention-to-treat analysis will be undertaken.Cox regression model will be used to compare primary outcome among study groups. Ethics and dissemination: Ethics committees at the sponsor institution and each centre where participants will be recruited approved the study protocol and the Informed Consent. Research findings will be published in peer-reviewed journals; additionally, results will be disseminated among region stakeholders. Trial registration number: NCT03881150; Pre-results . Date and version: 01 October 2019.